Evidence map›Paper›PMID 28678201›Full record

ArticleMolecules (Basel, Switzerland)2017

Characterization of Danaparoid Complex Extractive Drug by an Orthogonal Analytical Approach.

Cristina Gardini, Elena Urso, Marco Guerrini, René van Herpen, Pauline de Wit, Annamaria Naggi

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Danaparoid-Consensus Recommendations on Its Clinical Use.Pharmaceuticals (Basel, Switzerland) · 2024
    Review
  2. Review
  3. Review
  4. Article
  5. Non-Anticoagulant Heparins as Heparanase Inhibitors.Advances in experimental medicine and biology · 2020
    Review
  6. Article
  7. Article
  8. Rationale for the Role of Heparin and Related GAG Antithrombotics in COVID-19 Infection.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Cristina GardiniCentro Alta Tecnologia Istituto di Ricerche Chimiche e Biochimiche G. Ronzoni S.r.l., via G. Colombo 81, 20133 Milan, Italy. gardini@cat-ronzoni.it.
Elena UrsoIstituto di Ricerche Chimiche e Biochimiche G. Ronzoni S.r.l., via G. Colombo 81, 20133 Milan, Italy. urso@ronzoni.it.
Marco GuerriniIstituto di Ricerche Chimiche e Biochimiche G. Ronzoni S.r.l., via G. Colombo 81, 20133 Milan, Italy. guerrini@ronzoni.it.
René van HerpenAspen Oss B.V., Kloosterstraat 6, 5349 AB Oss, The Netherlands. rvanherpen@nl.aspenpharma.com.
Pauline de WitAspen Oss B.V., Kloosterstraat 6, 5349 AB Oss, The Netherlands. pdewit@nl.aspenpharma.com.
Annamaria NaggiIstituto di Ricerche Chimiche e Biochimiche G. Ronzoni S.r.l., via G. Colombo 81, 20133 Milan, Italy. naggi@ronzoni.it.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Danaparoid sodium salt, is the active component of ORGARAN, an anticoagulant and antithrombotic drug constituted of three glycosaminoglycans (GAGs) obtained from porcine intestinal mucosa extracts. Heparan sulfate is the major component, dermatan sulfate and chondroitin sulfate being the minor ones. Currently dermatan sulfate and chondroitin sulfate are quantified by UV detection of their unsaturated disaccharides obtained by enzymatic depolymerization. Due to the complexity of danaparoid biopolymers and the presence of shared components, an orthogonal approach has been applied using more advanced tools and methods. To integrate the analytical profile, 2D heteronuclear single quantum coherence (HSQC) NMR spectroscopy was applied and found effective to identify and quantify GAG component signals as well as those of some process signatures of danaparoid active pharmaceutical ingredient (API) batches. Analyses of components of both API samples and size separated fractions proceeded through the determination and distribution of the molecular weight (Mw) by high performance size exclusion chromatographic triple detector array (HP-SEC-TDA), chain mapping by LC/MS, and mono- (¹H and

Indexed as

AnimalsAnticoagulantsChondroitin SulfatesChromatography, GelChromatography, High Pressure LiquidDermatan SulfateHeparan SulfateIntestinal MucosaMagnetic Resonance SpectroscopyMolecular WeightSwineAnticoagulantsChondroitin SulfatesdanaparoidDermatan SulfateHeparan Sulfatecomponent quantitative analysisdanaparoid sodiumlow molecular weight glycosaminoglycansorthogonal multi-analytical methodssequence and compositional investigations

Identifiers

PMID28678201
PMCPMC6152146

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.